Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2026)

Xeris Biopharma Holdings has reported Change in Account Payables for 7 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 4.63% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $119000.0 (up 111.02% YoY), and the FY2025 full-year result was -$69000.0, up 99.28% from the prior year.
• Change in Account Payables for Q1 2026 stood at $4.2 million, up from -$1.7 million in the prior quarter.
• The five-year high for Change in Account Payables was $6.9 million in Q1 2023, with the low at -$5.2 million in Q4 2024.
• Historically, Change in Account Payables has averaged -$164176.5 across 5 years, with a median of $80000.0 in 2023.
• The largest YoY upside for Change in Account Payables was 456.57% in 2024 against a maximum downside of 2090.0% in 2024.
• Xeris Biopharma Holdings' Change in Account Payables stood at $690000.0 in 2022, then plunged by 151.16% to -$353000.0 in 2023, then tumbled by 1373.94% to -$5.2 million in 2024, then soared by 67.36% to -$1.7 million in 2025, then surged by 350.29% to $4.2 million in 2026.
• The last three Change in Account Payables figures came in at $4.2 million (Q1 2026), -$1.7 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.